Castuner

PCR Perspectives

PCR

Stay at the forefront of interventions for valvular heart disease, coronary, and structural interventions with expert insights and perspectives. These interviews explore the techniques, tools, and key topics shaping the ever-evolving field of interventional cardiology

Hosted on Acast. See acast.com/privacy for more information.

Sito del podcast

Ascoltalo nella tua app

Episodi

67 episodi

  1. How to understand and manage the large spectrum of shock phenotypes? 10:58
  2. Risk evaluation in asymptomatic patients: what is the current and future role of CT angiography? 11:07
  3. What are the latest developments in TAVI for aortic regurgitation? 6:43
  4. Why are most unstable coronary lesions missed by angiography? 9:31
  5. Who should we consider for tricuspid intervention in 2026? 5:34
  6. Perspectives from a neurologist and a cardiologist on LAA closure vs DOAC for stroke prevention 12:45
  7. How to anticipate a complex left atrial appendage closure intervention? 7:37
  8. What is the latest in the management of coronary artery disease in TAVI candidates? 8:12
  9. Reducing radiation exposure in the cath lab: What you need to know 3:54
  10. What is the role of AI in the cath lab of tomorrow? 5:10
  11. Which patient should have renal denervation in 2026? 6:49
  12. How to identify and manage vulnerable plaque? 6:14
  13. What is new in intracoronary physiology in 2026 and why does it matter? 10:13
  14. An interview with Andreas Grüntzig Ethica Award winner EuroPCR 2026 - Roxana Mehran 15:26
  15. Long-term mortality following PCI with DES vs. CABG for left main disease 7:20
  16. Coronary revascularisation in TAVI: meta-analysis of 4 Trials 9:37
  17. LAA closure vs. NOAC in patients with atrial fibrillation across age groups in the CHAMPION AF study 9:01
  18. What does ORBITA CTO tell us about CTO PCI? 7:10
  19. The art of prompting, how to ask AI the right questions? 4:41
  20. Why is TAVI a different procedure in patient with pure aortic regurgitation? 6:18
  21. How to manage current challenges of small aortic annulus? 8:13
  22. In what situation is emergency transcatheter valve intervention a valid alternative to surgery? 6:07
  23. What are the key considerations for transcatheter mitral paravalvular leak management? 6:13
  24. What are the key considerations when managing combined mitral and tricuspid regurgitation? 5:01
  25. How are the 2025 ESC EACTS valvular guidelines going to impact my TAVI programme? 6:52
  26. Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER? 6:25
  27. Is iatrogenic atrial septum defect closure a necessary procedure? 6:05
  28. How to manage patients with aortic stenosis and coronary artery disease? 4:24
  29. How are the 2025 ESC/EACTS valvular guidelines going to impact my mitral programme? 6:09
  30. What are the key steps in pre procedural assessment for successful LAA closure? 7:44
  31. The D-PACE scoring system - Can we predict high-grade conduction disturbances after TAVI? 5:36
  32. How do we meet the needs of women with heart valve disease? 6:09
  33. What are the key learnings from the 7-year follow-up of PARTNER 3? 8:30
  34. How are the new 2025 ESC/EACTS valvular guidelines going to impact my tricuspid programme? 5:23
  35. How to manage the challenges of TAVI in bicuspid disease? 5:52
  36. What are the essentials of the provisional strategy for non-left main true bifurcation lesions? 6:06
  37. EuroPCR 2025 Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis 6:39
  38. What is the latest in DCB practice? 7:48
  39. Redo TAVI: how to treat different TAVI platforms when they fail? 6:04
  40. What are the emerging indications for TAVI in 2025? 4:15
  41. How will EARLY-TAVI and NOTION-3 impact TAVI practice? 5:26
  42. Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study 6:49
  43. How to manage treatment dilemmas in STEMI patients with multivessel disease? 8:13
  44. Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome 3:51
  45. What are the fundamentals of an upfront two-stent strategy for bifurcation PCI? 7:04
  46. How to tailor transcatheter mitral therapies in 2025? A new era 6:24
  47. How to successfully approach calcified bifurcation lesions? 8:03
  48. Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies 5:57
  49. How to implement the diagnosis of INOCA in everyday practice? 5:47
  50. How to manage coronary artery disease in TAVI candidates? 7:28